HK1210957A1 - Effluz inhibitor compositions and methods of treatment using the same - Google Patents
Effluz inhibitor compositions and methods of treatment using the sameInfo
- Publication number
- HK1210957A1 HK1210957A1 HK15111835.9A HK15111835A HK1210957A1 HK 1210957 A1 HK1210957 A1 HK 1210957A1 HK 15111835 A HK15111835 A HK 15111835A HK 1210957 A1 HK1210957 A1 HK 1210957A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- effluz
- treatment
- methods
- same
- inhibitor compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676689P | 2012-07-27 | 2012-07-27 | |
PCT/US2013/052402 WO2014018932A2 (en) | 2012-07-27 | 2013-07-26 | Effluz inhibitor compositions and methods of treatment using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1210957A1 true HK1210957A1 (en) | 2016-05-13 |
Family
ID=48917738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111835.9A HK1210957A1 (en) | 2012-07-27 | 2015-12-02 | Effluz inhibitor compositions and methods of treatment using the same |
Country Status (12)
Country | Link |
---|---|
US (4) | US20140235631A1 (de) |
EP (1) | EP2877159B8 (de) |
JP (1) | JP6464084B2 (de) |
CN (1) | CN104736144B (de) |
AU (1) | AU2013295549B2 (de) |
BR (1) | BR112015001838B1 (de) |
CA (1) | CA2880236C (de) |
ES (1) | ES2656091T3 (de) |
HK (1) | HK1210957A1 (de) |
IN (1) | IN2015MN00408A (de) |
MX (1) | MX2015001194A (de) |
WO (1) | WO2014018932A2 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110064811A1 (en) | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
WO2018005994A1 (en) * | 2016-07-01 | 2018-01-04 | Neonc Technologies, Inc. | Methods of treating neurofibromatosis with perillyl alcohol |
US11147809B2 (en) | 2010-08-27 | 2021-10-19 | Neonc Technologies, Inc. | Methods of treating neurofibromatosis with perillyl alcohol |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2014046983A1 (en) | 2012-09-21 | 2014-03-27 | Intensity Therapeutic | Method of treating cancer |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150095055A1 (en) * | 2013-09-30 | 2015-04-02 | Horizon Pharma Usa, Inc. | Methods for processing a prescription drug request |
US10258615B2 (en) * | 2013-12-09 | 2019-04-16 | Thomas Jefferson University | Methods of treating a neurodegenerative disease in a mammal in need thereof |
KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
EP3204358B1 (de) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Cokristalle von modulatoren des transmembrankonduktanzregulators bei zystischer fibrose |
CN104352632B (zh) * | 2014-11-12 | 2017-11-24 | 扬子江药业集团北京海燕药业有限公司 | 一种柏艾胶囊作为肝转运体抑制剂的应用 |
CN107635563A (zh) * | 2014-11-17 | 2018-01-26 | 维多利亚联结有限公司 | 抗菌化合物 |
WO2016090240A1 (en) * | 2014-12-04 | 2016-06-09 | Astex Pharmaceuticals, Inc. | Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
GB201516905D0 (en) * | 2015-09-24 | 2015-11-11 | Stratified Medical Ltd | Treatment of Neurodegenerative diseases |
HUP1500618A2 (en) | 2015-12-16 | 2017-06-28 | Druggability Tech Ip Holdco Ltd | Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11110172B2 (en) | 2016-04-08 | 2021-09-07 | Imam Abdulrahman Bin Faisal University | Method for treating multiloculated hydrocephalus by administering an anti-IL6 receptor antibody |
WO2017192942A1 (en) * | 2016-05-06 | 2017-11-09 | THE USA, as representd by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | Methods for improving drug delivery across a p-glycoprotein expressing barrier |
CN107397721B (zh) * | 2016-05-18 | 2019-01-22 | 中国医学科学院基础医学研究所 | 含有布比卡因的药物组合物及其制备方法和用途 |
WO2017214468A1 (en) * | 2016-06-09 | 2017-12-14 | Tien Yang Der | Nanodroplet compositions for the efficient delivery of anti-cancer agents |
BR112018075984A2 (pt) * | 2016-06-13 | 2019-04-02 | Ascendia Pharmaceuticals, Llc | composição de distribuição de fármaco parenteral para liberação sustentada |
AU2017286979B2 (en) * | 2016-07-01 | 2023-04-27 | Dignity Health | Diagnostic or predictor of relapsing remitting multiple sclerosis |
US10912777B2 (en) * | 2016-12-22 | 2021-02-09 | Academia Sinica | Dipyridamole for use in treating SLC29A2 nuclear-expressing cancer |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2018204829A1 (en) * | 2017-05-04 | 2018-11-08 | University Of Maryland, Baltimore | Methods for preventing neural tube defects in diabetic pregnancy |
EP3634413A1 (de) * | 2017-06-09 | 2020-04-15 | Exelixis, Inc. | Flüssige darreichungsformen zur behandlung von krebs |
US20190038624A1 (en) * | 2017-08-03 | 2019-02-07 | Daniel Dung Truong | Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy |
WO2019104042A1 (en) * | 2017-11-21 | 2019-05-31 | University Of Iowa Research Foundation | Synthetically lethal nanoparticles for treatment of cancers |
FI3737378T3 (fi) * | 2018-01-12 | 2023-06-02 | Orion Corp | Palonosetronisilmätipat pahoinvoinnin ja oksentelun hoitoon tai ehkäisyyn |
MX2020009563A (es) | 2018-03-21 | 2020-10-05 | Izumi Tech Llc | Analogos deuterados del elacridar. |
US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
CN108484751B (zh) * | 2018-04-19 | 2020-06-23 | 西南大学 | 川陈皮素抗原及其制备方法与应用 |
CN109111533B (zh) * | 2018-05-10 | 2020-05-08 | 上海交通大学 | 硫酸肝素与fk506共轭物酶化学合成以及应用 |
TWI831259B (zh) | 2018-06-15 | 2024-02-01 | 漢達生技醫藥股份有限公司 | 包含達沙替尼十二烷基硫酸鹽組合物的膠囊 |
CN108670950B (zh) * | 2018-06-29 | 2020-10-02 | 深圳海王医药科技研究院有限公司 | 一种不含有机溶剂的虎杖苷药物组合物及其制备方法 |
CN108808030B (zh) * | 2018-07-03 | 2023-08-08 | 重庆大学 | 基于b-z振荡反应的脉冲电池设计 |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
TWI816881B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥(上海)股份有限公司 | 用於治療三陰性乳癌之組合療法 |
CN111617258A (zh) * | 2019-02-28 | 2020-09-04 | 江苏恒瑞医药股份有限公司 | 一种制备阿比特龙或其衍生物药物组合物的方法及其应用 |
CN110498784B (zh) * | 2019-05-20 | 2022-06-14 | 广东克冠达医药科技有限公司 | 一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用 |
CN111296417B (zh) * | 2020-04-01 | 2021-04-20 | 广东省农业科学院植物保护研究所 | 一种星·甲维悬浮剂及其制备方法与应用 |
US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
TWI813331B (zh) * | 2020-07-10 | 2023-08-21 | 長庚醫療財團法人林口長庚紀念醫院 | β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途 |
CN111840255B (zh) * | 2020-07-31 | 2022-03-01 | 北京丰帆生物医药科技有限公司 | 一种维拉帕米温敏缓释制剂及其制备方法和应用 |
KR102444571B1 (ko) * | 2020-11-18 | 2022-09-19 | 주식회사태준제약 | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 |
CN113384702A (zh) * | 2021-05-20 | 2021-09-14 | 温州医科大学附属第一医院 | H1组胺受体拮抗剂在制备治疗神经胶质瘤的药物中的应用 |
CN114917350B (zh) * | 2022-06-21 | 2023-06-13 | 重庆医科大学附属第二医院 | Cftr增强剂在注意缺陷与多动障碍中的应用及产品 |
WO2024074699A1 (en) * | 2022-10-07 | 2024-04-11 | Oculis Operations Sarl | Eye drop microsuspensions of mtor inhibitors |
CN115779089A (zh) * | 2022-11-28 | 2023-03-14 | 中国医学科学院肿瘤医院 | 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
JP3989175B2 (ja) | 1999-04-15 | 2007-10-10 | ブリストル−マイヤーズ スクイブ カンパニー | 環状タンパク質チロシンキナーゼ阻害剤 |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
PT1332137E (pt) | 2000-10-27 | 2006-07-31 | Novartis Ag | Tratamento de tumores estromais gastrintestinais |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
GB0119480D0 (en) * | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7924425B2 (en) * | 2005-06-27 | 2011-04-12 | The United States Of America As Represented By The Department Of Health And Human Services | Spatially selective fixed-optics multicolor fluorescence detection system for a multichannel microfluidic device, and method for detection |
US20070053869A1 (en) * | 2005-09-02 | 2007-03-08 | Yuichi Sugiyama | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
DE102006013531A1 (de) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
JP2010510988A (ja) * | 2006-11-28 | 2010-04-08 | マリナス ファーマシューティカルズ | ナノ粒子製剤とその製造方法およびその利用 |
WO2009083042A1 (en) * | 2007-12-31 | 2009-07-09 | Olaf Van Tellingen | Methods and means for the treatment of cancer |
-
2013
- 2013-07-26 CN CN201380050643.0A patent/CN104736144B/zh active Active
- 2013-07-26 CA CA2880236A patent/CA2880236C/en active Active
- 2013-07-26 BR BR112015001838-6A patent/BR112015001838B1/pt active IP Right Grant
- 2013-07-26 JP JP2015524485A patent/JP6464084B2/ja active Active
- 2013-07-26 WO PCT/US2013/052402 patent/WO2014018932A2/en active Application Filing
- 2013-07-26 ES ES13745549.9T patent/ES2656091T3/es active Active
- 2013-07-26 EP EP13745549.9A patent/EP2877159B8/de active Active
- 2013-07-26 AU AU2013295549A patent/AU2013295549B2/en active Active
- 2013-07-26 MX MX2015001194A patent/MX2015001194A/es unknown
- 2013-07-26 US US13/952,476 patent/US20140235631A1/en not_active Abandoned
-
2015
- 2015-02-25 IN IN408MUN2015 patent/IN2015MN00408A/en unknown
- 2015-12-02 HK HK15111835.9A patent/HK1210957A1/xx unknown
-
2019
- 2019-02-05 US US16/268,386 patent/US20190167630A1/en not_active Abandoned
-
2020
- 2020-09-11 US US17/017,674 patent/US20200405683A1/en not_active Abandoned
-
2021
- 2021-11-29 US US17/537,435 patent/US20220133679A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2880236A1 (en) | 2014-01-30 |
EP2877159A2 (de) | 2015-06-03 |
CN104736144A (zh) | 2015-06-24 |
EP2877159B8 (de) | 2018-02-14 |
WO2014018932A2 (en) | 2014-01-30 |
CA2880236C (en) | 2022-09-13 |
US20190167630A1 (en) | 2019-06-06 |
WO2014018932A8 (en) | 2014-12-31 |
JP2015523400A (ja) | 2015-08-13 |
IN2015MN00408A (de) | 2015-09-04 |
MX2015001194A (es) | 2015-11-23 |
BR112015001838A2 (pt) | 2017-07-04 |
CN104736144B (zh) | 2019-02-01 |
BR112015001838B1 (pt) | 2022-10-25 |
US20140235631A1 (en) | 2014-08-21 |
ES2656091T3 (es) | 2018-02-23 |
US20200405683A1 (en) | 2020-12-31 |
AU2013295549B2 (en) | 2018-04-19 |
EP2877159B1 (de) | 2017-11-08 |
US20220133679A1 (en) | 2022-05-05 |
JP6464084B2 (ja) | 2019-02-06 |
AU2013295549A1 (en) | 2015-03-19 |
WO2014018932A3 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
HRP20180953T1 (hr) | Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe | |
EP2847152A4 (de) | Zusammensetzungen und verfahren zur behandlung des stoffwechselsyndroms | |
EP2831001A4 (de) | Zusammensetzung zur behandlung von wasser und verfahren zur verwendung | |
EP2736528A4 (de) | Zusammensetzungen und verfahren zur behandlung von hiv | |
EP2834322A4 (de) | Biokohlezusammensetzungen und verfahren zur verwendung davon | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
EP2688594A4 (de) | Verfahren und zusammensetzungen zur krebsbehandlung | |
EP2884984A4 (de) | Therapeutische zusammensetzungen und verfahren | |
EP2906041A4 (de) | Zusammensetzungen und verfahren zur verwendung in einer inappetenzsteuerungsverbindung | |
EP2755668A4 (de) | Zusammensetzungen aus hyr1 und behandlungsverfahren damit | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
HK1220374A1 (zh) | 用於治療碳氧血紅蛋白血症的組合物和方法 | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
EP2800568A4 (de) | Zusammensetzungen, verwendungsverfahren dafür und behandlungsverfahren damit | |
EP3068431A4 (de) | Verfahren und zusammensetzungen zur behandlung von hcmv | |
ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
EP2809337A4 (de) | Ss-arrestineffektoren und zusammensetzungen und anwendungsverfahren dafür | |
EP2793875A4 (de) | Verfahren und zusammensetzungen zur behandlung von divertikulose | |
ZA201408053B (en) | Compositions and methods for the treatment of metabolic syndrome | |
EP2841164A4 (de) | Für die haut geeignete zusammensetzungen und verwendungsverfahren | |
GB201207064D0 (en) | Pharmaceutical compositions comprising 15-hetre and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: CORRECTION OF THE ENGLISH TITLE OF INVENTION FROM EFFLUZ INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME TO EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME |